PMID- 16897233
OWN - NLM
STAT- MEDLINE
DCOM- 20061222
LR  - 20181113
IS  - 0913-8668 (Print)
IS  - 0913-8668 (Linking)
VI  - 20
IP  - 3
DP  - 2006
TI  - Effects of sivelestat, a new elastase inhibitor, on IL-8 and MCP-1 production 
      from stimulated human alveolar epithelial type II cells.
PG  - 159-65
AB  - PURPOSE: The alveolar epithelial cell type II (AEC-II) is itself able to amplify 
      lung inflammation by producing inflammatory cytokines and chemokines, leading to 
      the activation and recruitment of phagocytes. Sivelestat, a new neutrophil 
      elastase inhibitor, has been shown to attenuate acute lung injury in animal 
      experiments. In the current study, we assessed the effects of sivelestat on the 
      production of chemokines from cultured A549 cells, a human AEC-II-like cell line. 
      METHODS: A549 cells were stimulated with endotoxin or tumor necrosis factor-alpha 
      in the presence of sivelestat (1-100 microg x ml(-1)). Culture supernatant levels 
      of interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) were 
      determined by enzyme-linked immunosorbent assay. The expression of IL-8 and MCP-1 
      mRNAs in stimulated A549 cells in the presence of sivelestat (100 microg x 
      ml(-1)) was quantified by real-time polymerase chain reaction. RESULTS: 
      Sivelestat, at 100 microg x ml(-1) reduced the accumulation of IL-8 and MCP-1 in 
      the culture medium. The high dose of sivelestat significantly inhibited the 
      expression of IL-8 mRNA in A549 cells. The drug also decreased MCP-1 mRNA 
      expression, although not significantly. CONCLUSION: These data suggest that a 
      high dose of sivelestat regulates the production of IL-8 and MCP-1 in AEC-II.
FAU - Misumi, Takuyo
AU  - Misumi T
AD  - Department of Anesthesia and Perioperative Medicine, Faculty of Medical Sciences, 
      Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Kobe 650-0017, 
      Japan.
FAU - Tanaka, Takanori
AU  - Tanaka T
FAU - Mikawa, Katsuya
AU  - Mikawa K
FAU - Nishina, Kahoru
AU  - Nishina K
FAU - Morikawa, Osamu
AU  - Morikawa O
FAU - Obara, Hidefumi
AU  - Obara H
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Anesth
JT  - Journal of anesthesia
JID - 8905667
RN  - 0 (Chemokine CCL2)
RN  - 0 (Endotoxins)
RN  - 0 (Interleukin-8)
RN  - 0 (RNA, Messenger)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 0 (Sulfonamides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - DWI62G0P59 (sivelestat)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Cells, Cultured/drug effects/immunology/metabolism
MH  - Chemokine CCL2/*biosynthesis/drug effects/immunology
MH  - Dose-Response Relationship, Drug
MH  - Endotoxins/administration & dosage
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epithelial Cells/*drug effects/immunology/metabolism
MH  - Glycine/*analogs & derivatives/pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Interleukin-8/*biosynthesis/immunology
MH  - Polymerase Chain Reaction/methods
MH  - Pulmonary Alveoli/*drug effects/immunology/metabolism
MH  - RNA, Messenger/immunology
MH  - Respiratory Mucosa/drug effects/immunology
MH  - Serine Proteinase Inhibitors/*pharmacology
MH  - Sulfonamides/*pharmacology
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/administration & dosage
EDAT- 2006/08/10 09:00
MHDA- 2006/12/23 09:00
CRDT- 2006/08/10 09:00
PHST- 2005/03/28 00:00 [received]
PHST- 2006/01/29 00:00 [accepted]
PHST- 2006/08/10 09:00 [pubmed]
PHST- 2006/12/23 09:00 [medline]
PHST- 2006/08/10 09:00 [entrez]
AID - 10.1007/s00540-006-0391-z [doi]
PST - ppublish
SO  - J Anesth. 2006;20(3):159-65. doi: 10.1007/s00540-006-0391-z.